Home » Newsletters » BioWorld Science

BioWorld Science

June 23, 2016

View Archived Issues

Susceptible mouse model of ZIKV infection as a tool for testing novel vaccines and antivirals

Validation of C1M as a prognostic biomarker in rheumatoid arthritis structural progression

Incyte initiates phase I/II study of INCAGN-01876 for advanced or metastatic solid tumors

Cytonics' recombinant A2M variants attenuate cartilage degeneration in osteoarthritis models

FDA grants orphan drug designation to ANAVEX 2-73

Cellular Dynamics and National Eye Institute sign CRADA

Spring Bank Pharmaceuticals begins dosing in ACHIEVE phase II program

STAT3 inhibition shows positive preclinical results for the treatment of breast cancer

Asahi Kasei Pharma and Orion establish strategic collaboration in pain

NIH committee recommends approval of Dimension Therapeutics' phase I/II study of DTX-301

Epizyme closes deal with Genentech for tazemetostat + atezolizumab study

Yumanity announces collaboration with the New York Stem Cell Foundation Research Institute

Nymox Pharmaceutical announces long-term fexapotide prostate cancer study results

NCI Cancer Centers and Celgene enter landmark research consortium and collaborations

Celgene's CC-115 shows signs of activity in phase I cancer trial

ArQule initiates phase I study of ARQ-751 in patients with advanced solid tumors

Bionomics receives funds as part of licensing agreement for PRMT5 inhibitors

FDA grants orphan drug designation to napabucasin for the treatment of gastric cancer

Janssen R&D reports antiviral compounds

Merck & Co. discloses HIV integrase inhibitors

Bayer Schering Pharma patents HSKM-B inhibitors

Aquinnah Pharmaceuticals patent describes TDP-43 inhibitors

Rapid responses seen with TNT-009 in patients with cold agglutinin disease

ASLAN Pharmaceuticals' varlitinib receives FDA orphan drug designation

Kailos Genetics and HCI collaborate to develop ctDNA test to monitor breast cancer recurrence

Allogeneic stem cell treatment with SB-623 shows promise in stroke patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 21, 2026
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...